These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32956248)

  • 1. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.
    Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV
    Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
    Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
    J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
    Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA
    Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with
    Delaunay K; Edeline J; Rolland Y; Lepareur N; Laffont S; Palard X; Bouvry C; Le Sourd S; Pracht M; Ardisson V; Noiret N; Bellissant É; Garin E
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1506-1517. PubMed ID: 30715571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.
    Datta Gupta SS; Shamim SA; Gamanagatti S; Gupta P; Khan MA; Mallia MB; Chirayil V; Dash A; Bal C
    Nucl Med Commun; 2024 Jun; 45(6):510-518. PubMed ID: 38632971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model.
    Tang IC; Luo TY; Liu SW; Chan SH; Kung HC; Peng CL; Lin WY; Chang Y; Lin WJ
    Nucl Med Biol; 2011 Oct; 38(7):1043-52. PubMed ID: 21831647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
    Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
    Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
    Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC
    J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.
    Kumar A; Bal C; Srivastava DN; Thulkar SP; Sharma S; Acharya SK; Duttagupta S
    Eur J Gastroenterol Hepatol; 2006 Feb; 18(2):219-23. PubMed ID: 16394805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
    Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
    Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma.
    Huang PW; Tsai SC; Luo TY; Kao CH; Lin WY
    Ann Nucl Med; 2013 Jul; 27(6):532-7. PubMed ID: 23479326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
    Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.